1	Title: BRIEF COMMUNICATION:
2	High level of Anti SARS-Co-V2 RBD Antibody one year post booster vaccine hospital
3	workers in Indonesia; Was second booster needed?
4	
5	Short Title: High Level of Anti SARSCoV2-RBD Antibody Level among Healthcare Worker,
6	Booster or Not?
7	
8	AUTHORS
9	Amila Hanifan Muslimah ¹ , Marita Restie Tiara ² , Hofiya Djauhari ² , Hafizh Dewantara ¹ ,
10	Evan Susandi ¹ , Agnes Rengga Indrati ³ , Bachti Alisjahbana ^{1,2} , Arto Yuwono Soeroto ¹ , Rudi
11	Wisaksana ^{1*}
12	¹ Department of Internal Medicine, Hasan Sadikin General Hospital, Faculty of Medicine,
13	Universitas Padjadjaran, Bandung, Indonesia
14	² Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung,
15	West Java, Indonesia
16	³ Department of Clinical Pathology, Hasan Sadikin General Hospital, Faculty of Medicine,
17	Universitas Padjadjaran, Bandung, West Java, Indonesia
18	
19	Corresponding author:
20	Rudi Wisaksana
21	Department Of Internal Medicine, Universitas Padjadjaran, Bandung, Indonesia.
22	Jl. Pasteur No.38, Pasteur, Sukajadi, Bandung City, West Java, Jawa Barat 40161
23	E-mail : rudi.wisaksana@unpad.ac.id
24	Abstract: 272 words
25	Word Count: 2739 words

26	Figure	1
		_

- 27 Table 1
- 28 CONFLICT OF INTEREST
- 29 None
- **30 ETHICAL APPROVAL**
- 31 Ethical clearance was provided by the Ethical Research Committee of Hasan Sadikin General Hospital (Number:
- 32 LB.02.01/X.6.5/117/2022)

33 DATA AVAILABILITY

34 The data used to support the findings of this study were included in the article.

35 Contributorship Statement

- 36 Amila Hanifan Muslimah: conceptualization, data curation, investigation, writing—original draft, writing— review,
- 37 and editing.
- 38 Rudi Wisaksana: conceptualization, data curation, investigation, writing-original draft, writing-review, editing,
- 39 validation, and supervision.
- 40 Marita Restie Tiara: conceptualization, data curation, investigation, writing-review, editing, validation, and
- 41 supervision.
- 42 Hafizh Dewantara: conceptualization, data curation, investigation.
- 43 Hofiya Djauhari: data curation, supervising laboratory work, conceptualization, investigation.
- 44 Evan Susandi : data curation, statistician, conceptualization, investigation.
- 45 Bachti Alisjahbana: conceptualization, investigation, writing-review
- 46 Arto Yuwono Soeroto: conceptualization, writing-original draft, writing-review, editing, validation, authorization
- 47 and supervision.
- 48 Agnes Rengga Indrati: conceptualization, data curation, investigation, writing-review, editing, validation, and
- 49 supervision.
- 50

51 ABSTRACT

52 Healthcare workers in Indonesia acquired a complete 2 doses of Sinovac in early 2021 and first booster dose of 53 Moderna in July 2021. In August 2022, the ministry of health prioritized healthcare workers to acquire the second 54 booster dose of Moderna as antibody levels from the year before may have waned. We conducted a sequential 55 serosurvey aimed to determine the level of SARS CoV2 S-RBD antibody reached by the first vaccine, after the first 56 booster, and before the second booster to understand the dynamics of the antibody level. COVID-19 antibody test was 57 conducted using the FastBioRBD^{im} test with a maximum limit detection level of 4000 BAU/mL. First serosurvey 58 which was conducted in June 2021, one to six months after Sinovac vaccination, showed a median antibody level of 59 41.4 BAU/mL (IQR 10 – 629.4 BAU/mL). The second serosurvey was conducted one month (August 2021) after the 60 first Moderna booster vaccine, and showed a median level of 4000 BAU/mL (IQR 3081-4000 BAU/mL). While the 61 last serosurvey conducted a year (August 2022) after the booster, showed 4000 BAU/mL (IQR 4000 – 4000 BAU/mL). 62 Only 39 (11.9%) healthcare workers have antibody levels below the maximum level of 4000 BAU./mL We did not 63 see the waning of antibody levels among healthcare workers approximately 1 year after the booster. It increases 64 perhaps due to the natural infection caused by the omicron variant outbreak in early 2022. Based on this fact, we 65 suggest considering if the second booster dose is really necessary. The limited vaccine supply can better be given to 66 the person or other high-risk groups of patients who has a low level of antibody based on serological testing.

67

68 Introduction

69 SARS-CoV-2 infection has become a health problem worldwide, including in Indonesia. (1) Presence of anti-SARS-70 CoV-2 antibody post-infection or due to vaccination has been confirmed to provide some protection against infection 71 and even more against severe COVID-19 disease. (2) Vaccination is therefore mandatory. However, current evidence 72 is still lacking about how many boosters are necessary for healthcare workers and the community at large. It is even 73 more difficult to determine because anti-SARS-CoV2 antibody level does affect by the type of vaccine we received, 74 exposure to natural infection as well as time since last vaccination/exposure, and internal factors like age and co-75 morbidity. (3,4)

76 Healthcare workers were greatly affected during the first wave in 2020 and the Delta strain of SARS CoV-2 outbreak

77 in July-September 2021. Our healthcare workers acquired complete 2 doses of Sinovac vaccine from January to June

78 2021. Sinovac was chosen as the vaccine used for healthcare workers because it was most readily available in 79 Indonesia at that time. Next, they acquire Moderna Booster in August 2021. During the Omicron outbreak in early 80 2022, many health care workers were also infected with COVID-19 but no severe infection was rarely observed. In 81 July 2022, the Indonesian Ministry of Health decided to prioritize a second mRNA vaccine for healthcare workers in 82 Indonesia. (5,6)

With the vaccine scheme that we acquired and the periodic exposures to COVID-19 during outbreaks, we came to wonder how high is our anti RBD-Level? And, is this second booster really necessary? Information about the level of Anti SARSCoV2-SRBD antibody can assist in evaluating the need for additional vaccination. (7) This study aims to describe the SARS CoV2 S-RBD antibody level among Hospital Workers in three consecutive serosurveys at different time points which can provide information on whether a booster is necessary.

88

89 Materials and methods

This research was conducted at Hasan Sadikin General Hospital as the top referral hospital for COVID-19 in West Java, Indonesia, with high exposure of COVID-19 infection healthcare workers during the pandemic. This study received approval from the Health Research Ethics Committee of Hasan Sadikin General Hospital Number LB.02.01/X.6.5/117/2022. It is a single-center, observational analysis study with a prospective design using primary data examining levels of SARS CoV 2 IgG S RBD antibody in hospital healthcare workers. Data consisted of basic participant information from interviews and results of antibody levels for SARS-COV-2 IgG S-RBD. All participants were vaccinated using Sinovac in the months January-June 2021.

97

98 Our first serosurvey was conducted in July 2021, right before the third vaccine dose or the first booster using the 99 Moderna vaccine. The second serosurvey was conducted in August 2021, one month after the provision of the first 100 Moderna booster Vaccine. The third serosurvey was conducted in August 2022, 12 months after the first Moderna 101 booster, right before the second Moderna booster that was programmed by the Ministry of Health.

102

103 Eligible participants were health workers of Hasan Sadikin General hospital collected by voluntary participation. All

104 participants were vaccinated with the complete two doses of the inactivated virus vaccine (Sinovac) and one booster

105 dose of mRNA-1273 (Moderna) full dose. This study used a convenience sampling method. All hospital staff who 106 followed these vaccination schemes and were willing to participate in the study were included in the survey.

107

108 We use the following operational definition. Physicians were all MDs, mostly specialists but also included general 109 practitioner working in the hospital. COVID-19 wards were areas that had the highest risk of spreading COVID-19, 110 including COVID-19 intensive care, general care, and emergency isolation room. History of close contact with 111 confirmed cases were face-to-face contact with probable cases or confirmed cases within one-meter radius and 15 112 minutes or more, direct physical touch with probable or confirmed cases, or people who provided direct care to 113 probable or confirmed cases without using standard personal protective equipment. Last COVID-19 infections (having 114 previous COVID-19 infections in between surveys) were a person who has positive RT-PCR results or rapid antigen 115 resulta with at least three symptoms of COVID-19 infection based on the interview.

116

117 Determination of anti-SARS-CoV2 S-RBD Antibody uses a point of care quantitative immunochromatographic assay 118 (FastBioRBD^{im}) produced by Wondfo, Guangzhou Biotech, China which was rebranded for distribution by PT 119 Biofarma, Indonesia (Persero). This equipment has a value range between 1 to 200 Arbitrary Unit (AU) where 1 is 120 regarded as the minimal level for being seropositive. We later multiplied the result by 20 to obtain the standard WHO 121 binding antibody unit (BAU). Therefore, 20 BAU/mL was the bottom limit for seropositivity, while the maximum 122 detection limit was 4000 BAU/mL. A similar fluorescent immunoassay test (Wondfo Finecare anti-RBD) has been 123 utilized and tested in Qatar. (8). To validate the FastBioRBDtm test, 71 randomly selected samples were tested using 124 the GenScript cPass SARS-CoV-2 Neutralization Antibody Detection Kit (Genscript Biotech, Leiden, Netherlands). 125 Briefly, serum samples as well as negative and positive controls were diluted 1:10 in sample dilution buffer, mixed 126 1:1 with HRP-RBD working solution, and incubated at 37 °C for 30 min. For more information sees in reference (9).

127

128 The baseline characteristics of participants described were factors that might influence SARS CoV2 S-RBD antibody 129 level, which was age, gender, occupation, comorbidity, last COVID-19 infection, work zone, history of close contact, 130 and levels of SARS-CoV-2 Ig G S-RBD. Data on baseline characteristic were obtained based on information from 131 the interview with a validated questionnaire. Anti-SARS CoV2 S-RBD antibody level was described in the descriptive

132 table as well in graphical form.

133

134 Results

135 On the first survey, we enrolled 570 person during the first booster vaccination day. After blood collection, these

136 subjects directly acquired the first booster of Moderna (full dose). One month after this first booster we enrolled 355

137 person in the second survey. One year after the first booster, we enrolled and collect serum samples from 330 persons

138 in the third survey right before the second booster of Moderna (figure). Participants' demography and characteristics

- 139 are summarized in the Table.
- 140

141 **Table. Baseline Characteristics of Participants**

Variables	First Survey	Second Survey	Third Survey	
	(n=570)	(n=355)	(n=330)	
Gender				
Male, n (%)	215 (38%)	120 (34%)	112 (34%)	
Female, n (%)	355 (62%)	235 (66%)	218 (66%)	
Age Category, median (IQR)	38 (32-50)	40 (33-52)	41 (34-52)	
18 – 30 y.o, n (%)	88 (15.5%)	55 (15.5%)	39 (12%)	
31 – 40 y.o, n (%)	223 (39.1%)	130 (36.7%)	122 (36.9%)	
41 – 50 y.o, n (%)	119 (20.7%)	72 (20.3%)	70 (21.2%)	
51 – 60 y.o, n (%)	108 (18.9%)	69 (19.4%)	79 (23.9%)	
>60 y.o, n (%)	33 (5.8%)	29 (8.1%)	20 (6%)	
Occupation				
Doctors, n (%)	283 (49.6%)	208 (58%)	155 (46%)^	
Non-Doctors, n (%)	287 (50.4%)	147 (42%)	175 (54%)	
Work-zone, n (%)				
In COVID-19 ward	147 (25.8%)	119 (33.5%)	102 (30.9%)	
Not in COVID-19 ward	254 (44.5%)	155 (43.7%)	134 (40.6%)	
Administrative work	169 (29.7%)	81 (22.8%)	94 (28.5%)	
History of Close contact with confirm case, n (%)	210 (36.8%)	15 (4.2%)	68 (20%)	
Last COVID 19 infections (having previous COVID 19	127 (22,2%)	34 (9.5%)	124 (37.5%)	
infection in between survey), n (%)				
Antibody Level (Median, IQR) BAU/mL	41.4	4000	4000	
	(10-629.4)	(3081 - 4000)	(4000 - 4000)	
Antibody Level Classification				
≥4000 BAU/mL	0 (0%)	205 (57.7%)	291 (88.1%)	
< 4000 BAU /mL	570 (100%)	150 (42.3%)	39 (11.9%)	

Notes: *n=frequency, %=percentage, ^ p value =0.05

144

The median age of the participants was 41 (IQR 34 to 52) years old, and 46% were practicing physicians. 64 (19.3 %) were specialists, and 91 (27.5%) were general physicians. Among the non-physician, 55 (16.6%) were nurses, 10 (3.03%) were laboratory staff and 73 (22.1%) were the administrative staff. Most of the participants belong to the non-covid ward group (254, 44.5%), while 147 (25.8%) were stationed and routinely care for COVID-19 patients in the ward.

150

During the first survey, the SARS CoV2 S-RBD antibody level median was 41,4 BAU/mL (Range 0.2 – 2.049.6
BAU/mL). One hundred eight (32.7 %) participants showed negative results for SARS-CoV-2 S-RBD antibody
(BAU/mL < 20) and 175 (30.7%) participants did not reach the median value (< 41.4 BAU/mL). No participant
reached a maximum detection level of 4000 BAU/mL. From the interview, 127 (%) reported having confirmed
COVID-19 illness since the beginning of the Pandemic.

156


In the second survey, we observed a median of 4000 BAU/mL (Range 840,4 – 4000). One hundred fifty (42.3%) participants had antibody levels below the maximum detection level of 4000 BAU/mL. No participant showed negative anti-SARS CoV2-SRBD. Within one month duration between the first and second survey, 34 participants reported having confirmed covid illness.

161

In the third survey, we obtained a median SARS CoV2 S-RBD antibody level of 4000 BAU/mL (range 144,8 – 4000 BAU/mL). In this survey 124 (37.5%) participants reported having confirmed COVID-19 illness within one year between the second and the third survey. The distribution of antibody levels based on the time of examination can be seen in the Figure.

166

167 Individuals with maximum antibody levels >4000 BAU/mL one month after 3^{rd} vaccination had more COVID-19 168 infections after 3^{rd} vaccination, with 57 participants (58.2%) and antibody levels >4000 BAU/mL twelve months after 169 3^{rd} vaccination having more COVID-19 infections with 106 participants (85.5%). The less infection in the second 170 survey probably was due to the shorter time interval between the first survey and the second survey. Antibody RBD Level



A bivariate analysis test was performed on factors potentially related to antibody levels on the last serosurvey.
Bivariate analysis showed that being a physician was associated with a lower SARS CoV2 S-RBD antibody levels.
Doctors have lower antibody levels (4000, Range 460-4000 BAU/mL) compared to non-doctors professions (4000,
Range 145-4000 BAU/mL) (p =0.05). The multivariate analysis gave the same result, which was that being a doctor
was a factor that had a significant result (adjusted OR 0.512 (95% CI 0.258-1.015) S1Table. Antibody levels twelve
months after the third vaccination did not reflect a protective effect against COVID infection 19.
Seventy-one randomly selected serum samples underwent validation tests with Genscript C-Pass. FastBioRBDtm

- 181 compared to C-Pass showed a correlation with r- value of 0.78 (95% CI 0.678-0.862) S2 Figure.
- 182
- 183 Discussion

We found an increasingly high antibody levels among healthcare workers in our hospital one year post booster. We think that this was due to natural exposure throughout the pandemic. Many believe that the antibody level that has been stimulated by the COVID-19 vaccine may gradually decline within several months (10,11). However, our observation did not show this situation.

188

189 Antibody levels were examined in participants about six months after being vaccinated with two Sinovac vaccinations 190 shown to reach a marginal level. There is still a substantial proportion of participants who showed negative serology. 191 A study in Turkey conducted in March 2021 observing Anti-RBD antibody levels 28 days post two doses of the 192 Sinovac vaccine in 330 health workers showed that 99.4% of health workers had a seropositive result with a median 193 of 154.78 BAU/mL. While only thirty-two-point-four percent of participants have maximum antibody levels. (12) 194 Antibody examination on healthcare workers in Hasan Sadikin General Hospital has a median time of 5,5 months 195 after the second dose of Sinovac vaccination, thus showing lower results. This is similar to a study conducted by 196 Fonseca et al in Brazil, in September 2021, that antibody levels 6 months after two doses of the Sinovac vaccine lower 197 levels with a median of 66.7 BAU/mL and 16 (2%) participants became seronegative. (13) The difference of these 198 findings can also be affected by the local epidemic dynamics in each country/region. (14)

199

200 The increase in antibody levels one month after receiving the first booster of Moderna vaccination was expected. Over 201 half of the respondents showed a maximum readable level of RBD antibody in this survey. However, there were still 202 a few subjects who showed only a moderate increase in antibody response. Adding a booster of mRNA vaccine in 203 subjects who have acquired inactivated vaccine was shown to increase their antibody level. A study in Chile has shown 204 that the group of subjects who acquired two Sinovac vaccines and a booster with the BNT162b2 RNA vaccine had 205 higher antibody levels 1 month after the third vaccination compared to the group given two Sinovac vaccines and the 206 third vaccine with Sinovac. (15) Several studies have also shown the effect of the Moderna vaccine, which 207 demonstrates a higher antibody response than the BNT vaccine.(16,17)

208

The third survey was conducted in August 2022, one year after the last booster of the Moderna vaccine and after we went through the Omicron outbreak in early 2022. In this survey, we found an even higher anti-RBD antibody level

among hospital staff and there were no signs of weaning of antibody level. The increased antibody level between the second survey to the third survey was most probably due to COVID-19 exposure during the Omicron outbreak. The result of our study is similar to the national serosurvey conducted in Indonesia. The Indonesian serosurvey has been conducted routinely in October and November 2021 and July 2022. The serosurvey also reveals an increasing antibody level in all communities in Indonesia. The vaccinated person has a higher antibody response than a non-vaccinated person. (18,19) A similar study in Italy conducted in January-November 2021 also showed similar results where anti-COVID RBD antibody increases months after receiving a booster vaccine. (20)

218

219 Our study showed that participants with high antibody levels experienced more COVID-19 infection. As we know 220 now from various reports, antibody level does not effectively prevent infection, especially with the new variant. 221 (21,22) But it significantly lowers the chances of having severe covid-19 illness. (23) The higher infection among 222 these groups could be due to their working environment or lifestyle which is already related to higher exposure to 223 COVID-19 since the beginning, therefore they have higher antibody response, and chances of new infection. Our data 224 and several other reports have consistently shown that (in developing countries) infections are mostly due to casual 225 contact rather than from the working environment. (24) Whereas casual contact was less affected by the hospital 226 protocol as well as national regulation.

227

Our study extensively uses the quantitative immunochromatographic assay which is easy to use and affordable. The test uses a cassette-based dry reagent with a small portable reader which can be utilized in a point-of-care setting. Compared to other tests, this test has good and acceptable validity. Our validation test of 71 samples with Genescript C-Pass showed a good correlation results. The Subject who has maximum detection level has a more than 90% result based on genscript SVNT assay had a sensitivity of 63.8%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 41.4%. A validation test in Qatar has selected 150 subject serum samples with rvalue of 0.7 (95% CI 0.60 to 0.80). (8)

235

Our study has some limitation. We collect the person invited to the survey based on the person who was willing to be tested. Thus, the number of samples, especially on the second and the third survey may not represent the whole hospital

238	staff population. However, within our observation, we have represented the whole range of types of workers and
239	exposure levels. Information about the previous COVID-19 was collected through interview or self-reporting. This
240	method may not be the most accurate as there might be information bias. Although based on other reports, self-
241	reporting may lead to lower prevalence than registered reports. (18,19)

243 Conclusion

We did not find a waning of humoral immunity to COVID-19 among healthcare workers in our hospital. Most probably this is due to the high transmission of SARS CoV2 and the outbreak of the omicron in early 2022. Most healthcare workers have a very high level of SARS CoV2 S-RBD antibody level 12 months post third COVID-19 vaccine dose. Based on this result, we should consider if a fourth vaccine dose is necessary for all. To make efficient use of the vaccine distributed, we suggest to incorporating antibody testing and only providing booster to those who have lower anti-RBD Antibody level.

250

251 CONFLICT OF INTEREST

252 None

253 ACKNOWLEDGEMENT

We are grateful for the support from Wondfo, Guanzhou Biotech, China, and PT Biofarma Indonesia (Persero) for providing the FastBioRBDtm fluorescent immunoassay reader and the rapid test reagents for our study. Thank you to Research and Innovation Indonesian Institute (BRIN) for providing initial operational support for conducting the study. We thank the director of Hasan Sadikin General Hospital for allowing this study to be conducted and the staff of the hospital who participated in this study. We thank the Dean of the Medical Faculty of Padjadjaran University who a provide laboratory facilities for sample management and testing in this study.

261 DATA AVAILABILITY

262 The data used to support the findings of this study were included in the article.

263

264 **REFERENCES**

- World Health Organization. Novel Coronavirus (COVID-19) Situation. 2022 Feb 25 [cited 25 February
 2022]. Available from: <u>https://covid19.who.int/.</u>
- Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection
 against COVID-19 in humans. Nat Rev Immunol. 2021;475–484.
- 3. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
 after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-387.
- Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
 double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021;S1473 3099(21):00681-2.
- 5. Minister of Health. Decree of the Minister of Health of the Republic of Indonesia. Technical Instructions for
 the Implementation of Vaccination in the Context of Combating the 2019 Corona Virus Disease (Covid-19)
 Pandemic;2022 [cited 20 February 2022]. Database: Management of Public Information on the Supreme
 Audit Board [internet]. Available from: https://peraturan.bpk.go.id/Home/Details/169665/permenkes-no-10tahun-2021.
- 280 Ministry of Health of the Republic of Indonesia. Circular Letter Number Hk.02.02/C/3615/2022 Concerning 6. 281 the 2nd Booster Dose of Covid-19 Vaccination for Health Human Resources. Ministry of Health of the 282 Republic Indonesia. 2022 July 28 [cited 30 2022]. of July Available from: 283 https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID 19-Dosis-284 Booster-2.pdf.
- Z85 7. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio
 286 M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
 287 Diagnostics (Basel). 2021;11(7):1135.c
- Shurrab FM, Younes N, Al-Sadeq DW, Liu N, Qotba H, Laith J. Abu-Raddad LJ, Nasrallah GK. Performance
 evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification
 of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individu. Int. J. Infect. Dis. 2022; 118:132–
 137.

- GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instruction for Use. In: Nanjing
 GenScript Diagnostics Technology Co. L, editor. 2022.
- 294 10. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
 295 after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-387.
- Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
 double-blind, randomized, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021;S14733099(21):00681-2.
- Dinc HO, Saltoglu N, Can G, Balkan II, Budak B, Ozbey D, Caglar B, Karaali R, Mete B, Tuyji Tok Y,
 Ersoy Y, Ahmet Kuskucu M, Midilli K, Ergin S, Kocazeybek BS. Inactive SARS-CoV-2 vaccine generates
 high antibody responses in healthcare workers with and without prior infection. Vaccine. 2022;40(1):52-58.
- 303 13. Fonseca MHG, de Souza TFG, de Carvalho Araújo FM, de Andrade LOM. Dynamics of antibody response
 304 to CoronaVac vaccine. J Med Virol. 2022;94(5):2139-2148.
- 305 14. Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. Cli Microbiol
 306 Rev. 2019;32(2):e00084-18.
- 307 15. Vargas, L., Valdivieso, N., Tempio, F. et al. Serological study of CoronaVac vaccine and booster doses in
 308 Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med. 2022; 20:216.
- 309 16. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response
 310 following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533-1535.
- 311 17. Collier AY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19
 312 vaccines. N Engl J Med. 2021;385(21):2010-2012.
- 313 18. Indonesian Health Ministry. National Survey Serology Results. 2022 March 18 [cited 24 January 2023] In:
- 314 COVID 19 Indonesia [Internet]: Jakarta: Indonesian Health Ministry. Available from : 315 https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-
- 316 <u>2021</u>

- 317 19. Indonesian Health Ministry. Third National Serology Survey. 2022 September [cited 24 January 2023] In:
 318 Indonesian Health Ministry [Internet]: Jakarta: Indonesian Health Ministry. Available from :
 319 https://www.youtube.com/watch?v=cgESZbe9rC0.
- 320 20. Lo Sasso B, Agnello L, Giglio RV, et al. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies
 321 before and after the third dose of the BNT162b2 vaccine. Sci Rep. 2022;12:8679.
- 322 21. Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody
- 323 Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants with Escape Mutations. Front
 324 Immunol. 2022;9(13): 801522.
- 325 22. Cromer D et al. Neutralizing antibody titers as predictors of protection against SARS-CoV-2 variants and the
 326 impact of boosting: a meta-analysis. Lancet Microbe 2022;3:e52–61.
- 327 23. Agrawal U et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters:
 328 pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland,
 329 Scotland, and Wales. Lancet 2022;400: 1305–20.
- Yu HJ, Hu YF, Liu XX, Yao XQ, Wang QF, Liu LP, Yang D, Li DJ, Wang PG, He QQ. Household infection:
 The predominant risk factor for close contacts of patients with COVID-19. Travel Med Infect Dis. 2020;
 36:101809.
- 552
- 333

335	Figure				
336	Fig 1. SARS CoV 2 S RBD Antibody Level Across Serosurveys				
337					
338	Tables				
339	Table 1. Baseline Characteristics of Research Subjects				
340 341	Sumpla	montour			
342	Supplementary S1 Table. Multivariate Analysis of Antibody Levels 12 Months after The Third Vaccination				
343					
344	0	S2 Figure. Surrogate Virus Neutralization Test (SVNT) Correlation with Anti-RBD FastBioRBD tm			
345 346	in Part	icipants after 12 Months of Third Vaccination			
347	DFFFI	DENCIEC			
		RENCES			
348	1.	World Health Organization. Novel Coronavirus (COVID-19) Situation. 2022 Feb 25 [cited 25 February			
349		2022]. Available from: <u>https://covid19.who.int/.</u>			
350	2.	Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection			
351		against COVID-19 in humans. Nat Rev Immunol. 2021;475–484.			
352	3.	Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning			
353		after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-387.			
354	4.	Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,			
355		and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,			
356		double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021;S1473-			
357		3099(21):00681-2.			
358	5.	Minister of Health. Decree of the Minister of Health of the Republic of Indonesia. Technical Instructions for			
359		the Implementation of Vaccination in the Context of Combating the 2019 Corona Virus Disease (Covid-19)			
360		Pandemic;2022 [cited 20 February 2022]. Database: Management of Public Information on the Supreme			
361		Audit Board [internet]. Available from: https://peraturan.bpk.go.id/Home/Details/169665/permenkes-no-10-			
362		tahun-2021.			

- 363 6. Ministry of Health of the Republic of Indonesia. Circular Letter Number Hk.02.02/C/3615/2022 Concerning 364 the 2nd Booster Dose of Covid-19 Vaccination for Health Human Resources. Ministry of Health of the 365 Republic 2022 July 28 [cited] 30 July 2022]. of Indonesia. Available from: 366 https://www.kemkes.go.id/downloads/resources/download/lain/Surat-Edaran-Vaksinasi-COVID 19-Dosis-367 Booster-2.pdf.
- Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, Ciaccio AM, Agnello L, Ciaccio
 M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine.
 Diagnostics (Basel). 2021 Jun 22;11(7):1135.
- Shurrab FM, Younes N, Al-Sadeq DW, Liu N, Qotba H, Laith J. Abu-Raddad LJ, Nasrallah GK. Performance
 evaluation of novel fluorescent-based lateral flow immunoassay (LFIA) for rapid detection and quantification
 of total anti-SARS-CoV-2 S-RBD binding antibodies in infected individu. Int. J. Infect. Dis. 2022; 118:132–
- 374 137.
- 375 9. GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instruction for Use. In: Nanjing
 376 GenScript Diagnostics Technology Co. L, editor. 2022.
- 377 10. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C, Fragaszy, et al. Spike-antibody waning
 378 after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385-387.
- 379 11. Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac,
 380 and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre,
 381 double-blind, randomized, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021;S1473382 3099(21):00681-2.
- Dinc HO, Saltoglu N, Can G, Balkan II, Budak B, Ozbey D, Caglar B, Karaali R, Mete B, Tuyji Tok Y,
 Ersoy Y, Ahmet Kuskucu M, Midilli K, Ergin S, Kocazeybek BS. Inactive SARS-CoV-2 vaccine generates
 high antibody responses in healthcare workers with and without prior infection. Vaccine. 2022;40(1):52-58.
- 386 13. Fonseca MHG, de Souza TFG, de Carvalho Araújo FM, de Andrade LOM. Dynamics of antibody response
 387 to CoronaVac vaccine. J Med Virol. 2022;94(5):2139-2148.
- 388 14. Zimmermann P., Curtis N. Factors That Influence the Immune Response to Vaccination. Cli Microbiol
 389 Rev. 2019;32(2):e00084-18.

- 390 15. Vargas, L., Valdivieso, N., Tempio, F. et al. Serological study of CoronaVac vaccine and booster doses in
 391 Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Med. 2022; 20:216.
- 392 16. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response
 393 following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533-1535.
- 394 17. Collier AY, Yu J, McMahan K, et al. Differential kinetics of immune responses elicited by Covid-19
 395 vaccines. N Engl J Med. 2021;385(21):2010-2012.
- 18. Indonesian Health Ministry. National Survey Serology Results. 2022 March 18 [cited 24 January 2023] In:
- 397 COVID 19 Indonesia [Internet]: Jakarta: Indonesian Health Ministry. Available from :
 398 <u>https://covid19.go.id/artikel/2022/03/18/hasil-survei-serologi-covid-19-di-indonesia-november-desember-</u>
- <u>399</u> <u>2021</u>
- Indonesian Health Ministry. Third National Serology Survey. 2022 September [cited 24 January 2023] In:
 Indonesian Health Ministry [Internet]: Jakarta: Indonesian Health Ministry. Available from :
 https://www.youtube.com/watch?v=cgESZbe9rC0.
- 403 20. Lo Sasso B, Agnello L, Giglio RV, et al. Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies
 404 before and after the third dose of the BNT162b2 vaccine. Sci Rep. 2022;12:8679.
- Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. A Detailed Overview of Immune Escape, Antibody
 Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants with Escape Mutations. Front
- 407 Immunol. 2022;9(13): 801522.
- 408 22. Cromer D et al. Neutralizing antibody titers as predictors of protection against SARS-CoV-2 variants and the
 409 impact of boosting: a meta-analysis. Lancet Microbe 2022;3:e52–61.
- 410 23. Agrawal U et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters:
 411 pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland,
 412 Scotland, and Wales. Lancet 2022;400: 1305–20.
- 413 24. Yu HJ, Hu YF, Liu XX, Yao XQ, Wang QF, Liu LP, Yang D, Li DJ, Wang PG, He QQ. Household infection:
- The predominant risk factor for close contacts of patients with COVID-19. Travel Med Infect Dis. 2020;
 36:101809.
- 416

417 Fig 1. SARS CoV 2 S RBD Antibody Level Across Serosurveys

- 418 Sequential serosurvey of SARS CoV2 S-RBD antibody before first booster Moderna, one month after first booster Moderna, and 12 months after
- 419 first booster Moderna. Most healthcare workers have very high level of SARS CoV2 S-RBD antibody level 12 months post third COVID 19 vaccine
- 420 dose. Second Moderna booster was given right after the blood taking off the third survey.

421

Antibody RBD Level




Fig 1. SARS CoV 2 S RBD Antibody Level

Figure